Eric Lian

Eric Lian

Auto-generated profile, based on publicly available information

Eric Lian

Queen's University, Kingston, Ontario, Canada

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 March 2017 in Journal of Visualized Experiments
Verified
Journal Article
Closed access
PDF file
SMSarah M. Maritan
Sarah M. Maritan
ELEric Y. Lian
Eric Y. Lian
Lois M. MulliganLois M. Mulligan
Lois M. Mulligan
Here, we describe a rapid and flexible protocol for the formation of 3D cell spheroids through cell aggregation. This is easily adapted ...

1 January 2017 in Endocrine-Related Cancer
Verified
Journal Article
Closed access
PDF file
ELEric Y Lian
Eric Y Lian
SMSarah M Maritan
Sarah M Maritan
JCJessica G Cockburn
Jessica G Cockburn
KKKatayoon Kasaian
Katayoon Kasaian
MCMathieu J F Crupi
Mathieu J F Crupi
Lois M. MulliganLois M. Mulligan
Lois M. Mulligan
The RET receptor tyrosine kinase mediates cell proliferation, survival and migration in embryogenesis and is implicated in the transformation and tumour progression in multiple cancers. RET is frequently mutated and constitutively activated in familial and sporadic thyroid carcinomas. As a result of alternative splicing, RET is expressed as two protein isoforms, RET9 and RET51, which differ in their unique C-terminal amino acids. These isoforms have distinct intracellular trafficking and associated signalling complexes, but functional differences are not well defined. We used shRNA-mediated knockdown (KD) of individual RET isoforms or of total RET to evaluate their functional contributions in thyroid carcinoma cells. We showed that RET is required for cell survival in medullary (MTC) but not papillary thyroid carcinoma (PTC) cells. In PTC cells, RET depletion reduced cell migration and induced a flattened epithelial-like morphology. RET KD decreased the expression of mesenchymal markers and matrix metalloproteinases and reduced anoikis resistance and invasive potential. Further, we showed that RET51 depletion had significantly greater effects on each of these processes than RET9 depletion in both MTC and PTC cells. Finally, we showed that expression of RET, particularly RET51, was correlated with malignancy in a panel of human thyroid tumour tissues. Together, our data show that RET expression promotes a more mesenchymal phenotype with reduced cell–cell adhesion and increased invasiveness in PTC cell models, but is more important for tumour cell survival, proliferation and anoikis resistance in MTC models. Our data suggest that the RET51 isoform plays a more prominent role in mediating these processes compared to RET9.

1 October 2017 in Journal of Cell Science
Verified
Journal Article
Open access
PDF file
BHBrandy D. Hyndman
Brandy D. Hyndman
MCMathieu Crupi
Mathieu Crupi
SPSusan Peng
Susan Peng
LBLeslie N. Bone
Leslie N. Bone
ARAisha N. Rekab
Aisha N. Rekab
Lois M. MulliganLois M. Mulligan
Lois M. Mulligan
The RET receptor tyrosine kinase is implicated in normal development and cancer. RET is expressed as two isoforms, RET9 and RET51, with unique C-terminal tail sequences that recruit distinct protein complexes to mediate signals. Upon activation, RET isoforms are internalized with distinct kinetics, suggesting differences in regulation. Here, we demonstrate that RET9 and RET51 differ in their abilities to recruit E3 ubiquitin ligases to their unique C-termini. RET51, but not RET9, interacts with, and is ubiquitylated by CBL, which is recruited through interactions with the GRB2 adaptor protein. RET51 internalization was not affected by CBL knockout but was delayed in GRB2-depleted cells. In contrast, RET9 ubiquitylation requires phosphorylation-dependent changes in accessibility of key RET9 C-terminal binding motifs that facilitate interactions with multiple adaptor proteins, including GRB10 and SHANK2, to recruit the NEDD4 ubiquitin ligase. We showed that NEDD4-mediated ubiquitylation is required for RET9 localization to clathrin-coated pits and subsequent internalization. Our data establish differences in the mechanisms of RET9 and RET51 ubiquitylation and internalization that may influence the strength and duration of RET isoform signals and cellular outputs. This article has an associated First Person interview with the first authors of the paper.

3 March 2016 in Human Molecular Genetics
Verified
Journal Article
Open access
PDF file
JSJoel Smith
Joel Smith
MRMartin L. Read
Martin L. Read
JHJon Hoffman
Jon Hoffman
RBRachel Brown
Rachel Brown
BBBeth Bradshaw
Beth Bradshaw
EWEmma R. Woodward
Emma R. Woodward
Familial medullary thyroid cancer (MTC) and its precursor, C cell hyperplasia (CCH), is associated with germline RET mutations causing multiple endocrine neoplasia type 2. However, some rare families with apparent MTC/CCH predisposition do not have a detectable RET mutation. To identify novel MTC/CCH predisposition genes we undertook exome resequencing studies in a family with apparent predisposition to MTC/CCH and no identifiable RET mutation. We identified a novel ESR2 frameshift mutation, c.948delT, which segregated with histological diagnosis following thyroid surgery in family members and demonstrated loss of ESR2-encoded ERβ expression in the MTC tumour. ERα and ERβ form heterodimers binding DNA at specific oestrogen-responsive elements (EREs) to regulate gene transcription. ERβ represses ERα-mediated activation of the ERE and the RET promoter contains three EREs. In vitro, we showed that ESR2 c.948delT results in unopposed ERα mediated increased cellular proliferation, activation of the ERE and increased RET expression. In vivo, immunostaining of CCH and MTC using an anti-RET antibody demonstrated increased RET expression. Together these findings identify germline ESR2 mutation as a novel cause of familial MTC/CCH and provide important insights into a novel mechanism causing increased RET expression in tumourigenesis.

21 September 2015 in Traffic
Verified
Journal Article
Closed access
PDF file
MCMathieu Crupi
Mathieu Crupi
PYPiriya Yoganathan
Piriya Yoganathan
LBLeslie N. Bone
Leslie N. Bone
ELEric Lian
Eric Lian
AFAndrew Fetz
Andrew Fetz
Lois M. MulliganLois M. Mulligan
Lois M. Mulligan

3 September 2020 in Oncogene
Verified
Journal Article
Closed access
PDF file
ELEric Y. Lian
Eric Y. Lian
BHBrandy D. Hyndman
Brandy D. Hyndman
SMSerisha Moodley
Serisha Moodley
SMSarah M. Maritan
Sarah M. Maritan
Lois M. MulliganLois M. Mulligan
Lois M. Mulligan